Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 966-972

  Liffraud, Cecile ^a   Quillet Mary, Anne ^a   Fournié, Jean Jacques ^a   Laurent, Guy ^a,b   Ysebaert, Loic ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b CHU PURPAN   (France)

Author keywords

Bcl 2; Chronic lymphocytic leukemia; enzastaurin; GSK 3 ; protein phosphatase 2A

Indexed keywords

ENZASTAURIN; FLUDARABINE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL; CELL CULTURE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; INDOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84859997845     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634041     Document Type: Article

References (31)

1. Pleyer L, Egle A, Hartmann TN, et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405-418.
2. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann Rev Immunol 2003;21:841-894. (Pubitemid 37174549)
3. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
4. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901. (Pubitemid 39096916)
5. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647. (Pubitemid 33126814)
6. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-4093. (Pubitemid 35332051)
7. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2002;6:283-294.
8. , Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2009;23:686-693.
9. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-378. (Pubitemid 40385478)
10. Ringshausen I, Oelsner M, Weick K, et al. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006;20:514-520. (Pubitemid 43291752)
11. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008;105:19643-19648.
12. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103:11713-11718. (Pubitemid 44182516)
13. Yan XJ, Albesiano E, Zanesi N, et al. Eff ect of rapamycin on mouse chronic lymphocytic leukemia and the development of non hematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006;66:915-920. (Pubitemid 43165958)
14. Holler C, Piñ ón JD, Denk U, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791-2794.
15. Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590-595. (Pubitemid 47508866)
16. Graff JR, McNulty AM, Hanna KR, et al. Th e protein kinase Cbetaselective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65:7462-7469. (Pubitemid 41161281)
17. Herbst R, Th ornton DE, Kies MS, et al. Phase I study of LY317615, a protein kinase Cβinhibitor. Proc Am Soc Clin Oncol 2002;21(Suppl.): Abstract 326.
18. Green LJ, Marder P, Ray C, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006;12:3408-3415.
19. Raab M, Breitkreutz I, Tonon G, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009;113:1513-1521.
20. zum Büschenfelde CM, Wagner M, Lutzny G, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141-152.
21. Dumstorf CA, Konicek BW, McNulty AM, et al. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Th er 2010;9:3158-3163.
22. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275-284.
23. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003;101:4122-4130. (Pubitemid 36857894)
24. Yamamoto M, Suzuki Y, Kihira H, et al. Expressions of four major protein Ser/Th r phosphatases in human primary leukemic cells. Leukemia 1999;13:595-600. (Pubitemid 29195289)
25. Janssens V, Longin S, Goris J. PP-2A holoenzyme assembly: in cauda venenum. Trends Biochem Sci 2008;33:113-121.
26. Th omas A, Pepper C, Hoy T, et al. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular diff erentiation and resistance to druginduced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2004;45:997-1008. (Pubitemid 38444677)
27. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia. Blood 2007;109:4964-4972. (Pubitemid 46827795)
28. Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2' s antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009;113:422-428.
29. Kuo WL, Liu J, Mauceri H, et al. Effi cacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Th er 2010;9:2814-2824.
30. Lin SS, Bassik MC, Suh H, et al. PP-2A regulates Bcl-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006;281:23003-23012.
31. Baudot AD, Jeandel PY, Mouska X, et al. Th e tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009;28:3261-3273.